PVLA Stock: Price, Earnings History and SEC Filings
Palvella Therapeutics, Inc. (PVLA) last traded at $146.15, down 3.58% on the latest session and up 6.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.52 against an analyst estimate of $-1.16, a miss of 31.0%.
$146.15 -3.58%
1 month+5.96%
52-week high$161.38
52-week low$71.55
Volume293,056
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PVLA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-1.52 | $-1.16 | -31.03% |
| Mar 2026 | May 7, 2026 | $-1.20 | $-0.90 | -33.33% |
| Dec 2025 | Mar 31, 2026 | $-1.08 | $-0.95 | -13.68% |
| Sep 2025 | Nov 11, 2025 | $-1.03 | $-0.85 | -21.18% |
PVLA beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for PVLA
SEC filing data is not available right now. You can search for PVLA on SEC EDGAR.
PVLA news
- Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026Oct 29, 2026 · finance.yahoo.com
- Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date SetOct 28, 2026 · finance.yahoo.com
- Palvella Gets FDA Priority Review For QTORIN Rapamycin; Decision Expected In February 2027; Stock UpOct 28, 2026 · rttnews.com
- Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline ExpandsOct 25, 2026 · marketbeat.com
- What Does Palvella Therapeutics (PVLA) NDA Progress Mean After Its Phase 3 Data?Oct 24, 2026 · finance.yahoo.com
- Ligand to Host Investor Day on December 8, 2026Oct 22, 2026 · finance.yahoo.com
- William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageOct 21, 2026 · finance.yahoo.com
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. (PVLA) is a US-listed public company on Nasdaq.